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Summary of findings {#CD010458-sec1-0001}
===================

Summary of findings for the main comparisonSummary of findings table 1**Tafenoquine vs placebo/no hypnozoite treatment in people with *Plasmodium vivax* malariaPatient or population:** Adults and children with*P. vivax* malaria **Settings:***P. vivax* endemic areas **Intervention:** Tafenoquine. Both intervention and control received chloroquine treatment. **Comparison:** No hypnozoite treatment.**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskCQ aloneTQ plus CQRecurrent *P. vivax* parasitaemia during six months of follow‐up300 mg as a single doseRR 0.19** (0.08 to 0.41)110 (1 trial)⊕⊕⊕⊝ **moderate**^1,2,3^**57 per 10011 per 100**\
(5 to 23)**500 mg or 600 mg as a single doseRR 0.14** (0.06 to 0.34)122 (2 trials)⊕⊕⊕⊝ **moderate**^4,5,6,7^**57 per 1008 per 100**\
(3 to 19)**1800 mg to 3000 mg in divided dosesRR 0.05** (0.01 to 0.23)63 (2 trials)⊕⊕⊝⊝ **low**^5,7,8,9^**57 per 1003 per 100** (1 to 13)**Serious adverse events6 per 1006 per 100** (2 to 16)**RR 0.94** (0.34 to 2.59)358 (3 trials)⊕⊕⊝⊝ **low**^10,11^\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **CQ:** Chloroquine; **TQ:** Tafenoquine; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Summary of findings 2Summary of findings table 2**Tafenoquine vs primaquine in people with *Plasmodium vivax* malariaPatient or population:** Adults and children with*P. vivax* malaria **Settings:***P. vivax* endemic areas **Intervention:** Tafenoquine. Both intervention and control received chloroquine treatment. **Comparison:** primaquine (standard 14 day regimen)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskPQ and CQTQ and CQRecurrent *P. vivax* parasitaemia during six months of follow‐up300 mg as a single doseRR 0.41** (0.15 to 1.14)79 (1 trial)⊕⊕⊝⊝ **low**^1,2,3^**26 per 10011 per 100**\
(4 to 30)**600 mg as a single doseRR 0.29** (0.1 to 0.84)98 (2 trials)⊕⊕⊝⊝ **low**^4,5^**25 per 1007 per 100**\
(3 to 21)**1800 mg to 2100 mg in divided dosesRR 0.06** (0.00 to 1.1)38 (1 trial)⊕⊕⊝⊝ **low**^3,5^**25 per 1002 per 100** (0 to 27)**Serious adverse events12 per 1005.5 per 100** (2 to 13)**RR 0.47** (0.2 to 1.08)323 (2 trials)⊕⊕⊝⊝ **low**^6,7^\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **CQ:** Chloroquine; **PQ:** Primquine; **TQ:** Tafenoquine; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^3]

Background {#CD010458-sec1-0002}
==========

Malaria remains an important cause of illness and death in many tropical countries. In 2011, 216 million cases of malaria were estimated to have occurred globally and in 2010 there were approximately 655,000 deaths due to malaria ([@CD010458-bbs2-0041]). Global malaria eradication efforts have resulted in a decrease in mortality and morbidity, with global mortality from malaria falling by 25% since 2000 ([@CD010458-bbs2-0041]). Most malaria cases are caused by the species *Plasmodium falciparum* and *Plasmodium vivax*. *P. falciparum* causes a more severe form of malaria with multi‐organ involvement ([@CD010458-bbs2-0025]). *P. vivax* is less virulent than *P. falciparum* and seldom causes death. However, it causes substantive illness‐related burden in endemic areas. The incidence of *P. vivax* infection has become particularly important in countries aiming for malaria elimination. Currently, there are 32 such countries, of which, 25 are mainly targeting elimination (interruption of transmission without local cases) of*P. vivax*. Another 67 countries are working towards reducing and controlling the high burden of malaria mortality and morbidity ([@CD010458-bbs2-0024][@CD010458-bbs2-0025]). *P. vivax* infection has been treated with chloroquine (CQ) but resistance to this widely available drug has been reported on all continents in which malaria caused by *P. vivax* is endemic ([@CD010458-bbs2-0038]; [@CD010458-bbs2-0040]). Eradication of liver stages of the disease is necessary to avoid relapses. Due to the large number of infections reported, malaria caused by *P. vivax* is increasingly being identified as an important public health problem in endemic areas ([@CD010458-bbs2-0040]).

Description of the condition {#CD010458-sec2-0001}
----------------------------

The life cycles of *P. falciparum* and *P. vivax* differ. *P. vivax* can have dormant forms in the hepatocytes, known as hypnozoites, which can remain dormant for weeks or even months. Thus, a single infection with *P. vivax* can be responsible for a relapse or series of relapses after an apparent cure. Therefore, eradication of the dormant hepatic forms of the *P. vivax* parasite is necessary to prevent recurrences. Treatment of people infected with *P. vivax* with blood schizonticidal agents alone will not result in complete cure as these agents are not capable of clearing the hypnozoites.

Description of the intervention {#CD010458-sec2-0002}
-------------------------------

Primaquine (PQ), an 8‐aminoquinoline, was first licensed for use in the 1950s by the Food and Drug Administration (FDA), United States ([@CD010458-bbs2-0032]), for treatment of vivax malaria. It is the only licensed drug capable of eliminating the vivax hypnozoites. Without administration of PQ in adequate doses, complete cure of patients with *P. vivax* infection is difficult, and patients often have relapses of clinical disease ([@CD010458-bbs2-0019]; [@CD010458-bbs2-0026]). There are several potential alternatives to PQ but tafenoquine (TQ) has been the most extensively studied option over the last 15 years. TQ is an 8‐aminoquinoline ([@CD010458-bbs2-0039]) and is a synthetic analogue of PQ ([@CD010458-bbs2-0003]). It has potential to be useful in regimens for prophylaxis and radical cure of *P. vivax* malaria.

PQ can precipitate haemolysis (which can be life‐threatening) in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency, an X‐linked recessive condition ([@CD010458-bbs2-0035]). In addition, it has other undesirable side effects such as methaemoglobinaemia and gastrointestinal disturbances ([@CD010458-bbs2-0022]). PQ resistance has been reported as isolated cases from different areas even after it has been administered in adequate doses according to body weight ([@CD010458-bbs2-0023]; [@CD010458-bbs2-0027]; [@CD010458-bbs2-0032]; [@CD010458-bbs2-0036]). PQ treatment has to be continued for 14 days, which often leads to poor compliance ([@CD010458-bbs2-0032]).

A search for a replacement drug for PQ in its curative role has been ongoing for the last few decades. The characteristics of an ideal replacement would be: a) has a shorter duration of treatment, b) has better efficacy in clearing hypnozoites, c) is free from the significant side effects of PQ such as haemolysis in individuals with G6PD deficiency and d) lower chance of the parasite developing resistance to the drug. Several options have been explored in this regard, including TQ, bulaquine, tinidazole and imidazolidinone. Bulaquine is the pro‐drug of PQ and is currently not licensed for sale outside India ([@CD010458-bbs2-0039]). Of other options, only TQ has been tested to show promising results for both prevention and radical cure in individual trials. Also, its shorter duration of therapy makes it an attractive option to improve adherence. It also causes haemolysis, and its longer half‐life makes any haemolytic effect more prolonged and thus potentially more serious. In 2013, the FDA designated TQ as a breakthrough therapy. This Cochrane review will pool the evidence from all RCTs on use of TQ for radical cure of*P. vivax* malaria to answer key questions on its efficacy and adverse event profile as compared to no treatment or PQ.

How the intervention might work {#CD010458-sec2-0003}
-------------------------------

The exact mechanism of action of TQ is not yet known. Based on early in vitro and animal studies, some believed it to be longer acting and more effective than PQ ([@CD010458-bbs2-0003]). Preclinical studies showed better activity of TQ compared to PQ against both hepatic and erythrocytic forms of the parasite. Phase I and II trials have been conducted to evaluate its safety ([@CD010458-bbs2-0020]; [@CD010458-bbs2-0021]). It has been more than a decade since TQ has been studied for treating *P. vivax* malaria.

Why it is important to do this review {#CD010458-sec2-0004}
-------------------------------------

PQ is a unique drug in combating vivax malaria but has side effects, which can sometimes be serious in people with G6PD deficiency. The long duration of treatment also leads to poor adherence. TQ is a possible alternative that has shown promise in replacing PQ and it can be administered as a single dose or in much shorter treatment regimens. Therefore, it is important to establish the effects of TQ from available data for preventing relapses of vivax malaria after an acute infection.

Objectives {#CD010458-sec1-0003}
==========

To assess the effects of tafenoquine in people with *P. vivax* infection.

Methods {#CD010458-sec1-0004}
=======

Criteria for considering studies for this review {#CD010458-sec2-0005}
------------------------------------------------

### Types of studies {#CD010458-sec3-0001}

Randomized controlled clinical trials (RCTs). We excluded quasiRCTs..

### Types of participants {#CD010458-sec3-0002}

Adults and children with confirmed (clinical and parasitological) diagnosis of *P. vivax* malaria.

We included trials where people with G6PD deficiency have been excluded, and in populations without screening for G6PD deficiency.

### Types of interventions {#CD010458-sec3-0003}

#### Intervention {#CD010458-sec4-0001}

Tafenoquine

#### Control {#CD010458-sec4-0002}

No drug or placebo;

Primaquine in standard WHO 14‐day regimen

Both intervention and control groups must have received the same treatment, either CQ or an ACT, for the blood‐borne stage of the *P. vivax* infection.

### Types of outcome measures {#CD010458-sec3-0004}

Episodes of *P. vivax* parasitaemia during follow‐up

Serious adverse events:death, symptomatic haemolysis, symptomatic methaemoglobinaemia, any other potentially life threatening observation or complaint that required treatment and monitoring by further investigations.

Any adverse events: all adverse effects either reported by subjects or elicited by investigators during treatment and follow‐up.

Search methods for identification of studies {#CD010458-sec2-0006}
--------------------------------------------

We identified all relevant trials regardless of language or publication status (published, unpublished, in press and in progress). There were no time limits for the search.

### Electronic searches {#CD010458-sec3-0005}

We searched the following databases using the search terms detailed in [Appendix 1](#CD010458-sec2-0016){ref-type="app"}: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; MEDLINE; EMBASE; CINAHL; SCOPUS; and LILACS. We also searched the World Health Organization (WHO) International Clinical Trial Registry Platform and the metaRegister of Controlled Trials (mRCT) for ongoing trials using \"tafenoquine\" and \"malaria\" as search terms. The date of the last search for all databases was 13 April 2015 and included all entries within these databases up to this date.

### Searching other resources {#CD010458-sec3-0006}

#### Conference proceedings {#CD010458-sec4-0003}

We searched relevant proceedings of the Multilateral Initiative on Malaria (MIM) Pan‐African Malaria Conference and the American Society of Tropical Medicine and Hygiene Annual Meeting from 1990 onwards for trial information. The date of the last search was 13 April 2015.

#### Researchers {#CD010458-sec4-0004}

We contacted researchers working in the field and the WHO for unpublished and ongoing trials.

#### Reference lists {#CD010458-sec4-0005}

We checked the reference lists of existing reviews and of all trials identified by the above methods.

Data collection and analysis {#CD010458-sec2-0007}
----------------------------

### Selection of studies {#CD010458-sec3-0007}

We (SR, CR and SDF) independently screened all trials identified by the search strategy and obtained full reports of potentially relevant trials. We independently applied the inclusion criteria to the full reports using an eligibility form and scrutinized publications to ensure each trial was included in the review only once. If necessary, we contacted the trial authors for clarification. Any disagreement was resolved by consensus. We have listed the ineligible trials and the reasons for their exclusion in the \'[Characteristics of excluded studies](#CD010458-sec2-0020){ref-type="sec"}\' table.

### Data extraction and management {#CD010458-sec3-0008}

We (SR, CR and SDF) extracted data from the selected trials and independently recorded outcomes. We developed and used a data extraction and assessment form suited for the needs of this review according to the instructions provided by The Cochrane Collaboration ([@CD010458-bbs2-0031]). We used [@CD010458-bbs2-0037] for data analysis and storage, and created \'Summary of findings\' tables with [@CD010458-bbs2-0028] software. In each of the selected trials, we identified key information such as demographic characteristics of selected populations, G6PD status of the subjects, trial design and measures taken to minimize bias, treatment offered in different trial arms (with respect to dose and duration), duration of follow‐up, adverse events and reported outcomes. We also noted the limitations in each of the trials.

### Assessment of risk of bias in included studies {#CD010458-sec3-0009}

We (SR, CR and SDF) independently assessed the risk of bias for each included trial using a \'Risk of bias\' assessment form. We resolved any discrepancies between the results of the \'Risk of bias\' analysis through discussion and consensus. If data were unclear or not reported, we wrote to the trial authors for clarification. We did not calculate quality scores for individual trials as it is not perceived by some authors as an objective measure of risk of bias ([@CD010458-bbs2-0029]).

We assessed the risk of bias for individual trials using the Cochrane \'Risk of bias\' tool. This covers six domains of bias: allocation (selection bias), blinding (performance bias and detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other potential sources of bias. Furthermore, we summarized the risk of bias for individual trials in a \'Risk of bias\' table.

### Measures of treatment effect {#CD010458-sec3-0010}

We expressed the effect of treatment within trials as risk ratio (RR) for dichotomous outcomes (for example, relapse of vivax malaria, new infections of vivax malaria). We defined the level of significance of differences according to the Chi^2^ statistic of P \< 0.05. For all results, we calculated 95% confidence intervals (CIs) and performed meta‐analyses if sufficient data were available. We split the control groups between trial arms of a single trial where appropriate for meta‐analysis.

### Unit of analysis issues {#CD010458-sec3-0011}

We did not identify any cluster‐RCTs in the search. Trials used different doses of TQ in multiple‐treatment arms against a control. If the doses were identical in certain trial groups, we combined them for pair‐wise comparison in a meta‐analysis. When comparing different TQ doses, we split the control group to avoid duplication in data entry.

### Dealing with missing data {#CD010458-sec3-0012}

We contacted the corresponding author of one trial ([@CD010458-bbs2-0001]) regarding data not reported in the paper and we obtained relevant data. No trials were excluded due to missing data.

### Assessment of heterogeneity {#CD010458-sec3-0013}

We assessed heterogeneity using the I^2^ statistic ([@CD010458-bbs2-0030]), which examines the percentage of total variation across studies that are due to heterogeneity rather than chance. An I^2^ statistic value \> 70% indicates a high level of heterogeneity.

### Assessment of reporting biases {#CD010458-sec3-0014}

Since an insufficient number of RCTs met our inclusion criteria (\< 10 trials) for each primary objective, we could not construct funnel plots to look for evidence of publication bias.

### Data synthesis {#CD010458-sec3-0015}

We analysed data using [@CD010458-bbs2-0037]. CR conducted the initial analysis, and SR and SDF independently double checked and performed recalculations. We compared relapses following treatment between groups treated with TQ‐containing drug regimens against CQ alone or CQ plus PQ. Also, we compared the reported adverse events between TQ and controls. We used a fixed‐effect model for analysis (and rechecked for any differences of results in a random‐effects model).

### Subgroup analysis and investigation of heterogeneity {#CD010458-sec3-0016}

When several trials were combined in a meta‐analysis, we calculated heterogeneity to express the treatment effect of TQ and CQ versus CQ alone or CQ plus PQ. We presented data in subgroups depending on the different doses of TQ used and whether single doses or split doses were used.

### Sensitivity analysis {#CD010458-sec3-0017}

We did not perform a sensitivity analysis as only three trials were eligible for a valid comparison in a meta‐analysis.

Results {#CD010458-sec1-0005}
=======

Description of studies {#CD010458-sec2-0008}
----------------------

See: [Characteristics of included studies](#CD010458-sec2-0019){ref-type="sec"}, [Characteristics of excluded studies](#CD010458-sec2-0020){ref-type="sec"} and [Characteristics of ongoing studies](#CD010458-sec2-0021){ref-type="sec"}. We have given a summary of drug doses used in each trial arm of all included trials for ease of comparison ([Table 5](#CD010458-tbl-0005){ref-type="table"}).Table 1Summary of doses of drugs used in each of the trial arms**TrialTrial groups and tafenoquine dosesComments**[@CD010458-bbs2-0001]50 mg single dose100 mg single dose300 mg single dose600 mg as a single doseNo TQ; CQ followed by PQ 15 mg/day for 14 daysNo TQ; CQ onlyIn all trials, all patients received the standard treatment of CQ 1500 mg over 3 days to clear the initial parasitaemia.\
There were no reports of CQ resistance.\
 [@CD010458-bbs2-0002]300 mg/day for 7 days (total dose 2100 mg)500 mg/day for 3 days, two courses separated by 1 week (total dose 3000 mg)500 mg as a single doseNo TQ; CQ only[@CD010458-bbs2-0003]300 mg/day for 7 days (total dose 2100 mg)600 mg/day for 3 days (total dose 1800 mg)600 mg as a single doseNo TQ; CQ onlyNo TQ; CQ followed by PQ 15 mg/day for 14 days[^4]

### Results of the search {#CD010458-sec3-0018}

The results of the search, after excluding duplicate and irrelevant articles, yielded 15 papers that we deemed potentially useful for this Cochrane review ([Figure 1](#CD010458-fig-0001){ref-type="fig"}). However, only three trials met the inclusion criteria.Figure 1PRISMA flow diagram indicating the process of inclusion and exclusion of studies.

### Included studies {#CD010458-sec3-0019}

Three individually RCTs met the inclusion criteria ([@CD010458-bbs2-0001]; [@CD010458-bbs2-0002]; [@CD010458-bbs2-0003]). All patients received a full course of CQ to treat their *P. vivax* infection (1500 mg over three days). Comparisons included TQ + CQ versus CQ only (all three trials) and TQ + CQ versus CQ + PQ (two trials). No trials were conducted with ACTs as the background treatment.

All trials were in symptomatic patients with uncomplicated vivax malaria, and all trials excluded patients with G6PD deficiency, pregnant females and children.

Two trials were conducted in Bangkok, Thailand ([@CD010458-bbs2-0002]; [@CD010458-bbs2-0003]) and the latest trial was a multicentre trial in Thailand, India, Peru and Brazil ([@CD010458-bbs2-0001]). The earlier two trials examined comparatively high doses of TQ starting from 500 mg ([@CD010458-bbs2-0002]) or 600 mg ([@CD010458-bbs2-0003]) administered as single doses and 1800 to 3000 mg administered as split doses over three to seven days. [@CD010458-bbs2-0001] tested single doses of TQ at strengths of 50, 100, 300 and 600 mg. The main outcomes assessed were: a) recurrences of vivax malaria up to six months follow‐up and b) adverse events. We contacted the authors of [@CD010458-bbs2-0001] for details not published in the paper (exact number of relapses during follow‐up) and we included the data in this analysis.

### Excluded studies {#CD010458-sec3-0020}

We excluded randomized trials on prophylaxis, non‐controlled trials, case reports and pharmacokinetic studies (see [Characteristics of excluded studies](#CD010458-sec2-0020){ref-type="sec"}).

Risk of bias in included studies {#CD010458-sec2-0009}
--------------------------------

For a summary of risk of bias please see the \'[Characteristics of included studies](#CD010458-sec2-0019){ref-type="sec"}\' table and [Figure 2](#CD010458-fig-0002){ref-type="fig"}.Figure 2Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.

All three included trials were described as randomized with computer generated sequence allocation. However in [@CD010458-bbs2-0003], some randomizations were eliminated and a few others were shifted between groups to balance the number of participants recruited in each group. Therefore we were unclear regarding the selection bias.

Both [@CD010458-bbs2-0002] and [@CD010458-bbs2-0003] were open label studies. However, the primary outcome of vivax parasitaemia was unlikely to be influenced by this fact as long as the microscopists were blinded. [@CD010458-bbs2-0002] mentions that the microscopists were blinded but [@CD010458-bbs2-0003] does not. So we judged that [@CD010458-bbs2-0002] was at low risk of bias and [@CD010458-bbs2-0003] was at unclear risk of bias. [@CD010458-bbs2-0001] was a double blind trial at low risk of bias. [@CD010458-bbs2-0002] had a high attrition rate (27% of total sample during the first two months). It was lower but significant in [@CD010458-bbs2-0003] (15% of total sample were lost to follow‐up during the first two months). The attrition rates were less than 6% for any of the trial arms in [@CD010458-bbs2-0001] which had a low risk of attrition bias.

All missing patients were accounted for and there was no reporting bias in all trials.

Effects of interventions {#CD010458-sec2-0010}
------------------------

See: [Table 1](#CD010458-tbl-0001){ref-type="table"}; [Table 2](#CD010458-tbl-0002){ref-type="table"}

### 1. Tafenoquine versus no hypnozoite treatment {#CD010458-sec3-0021}

All three trials included arms that evaluated TQ against no specific anti‐hypnozoite drug. The TQ doses varied from 50 to 600 mg in single doses and from 1800 to 3000 mg in spilt doses over three to seven days. All patients in all included arms received CQ 1500 mg for three days.

#### Recurrent *P. vivax* parasitaemia during six months follow‐up {#CD010458-sec4-0006}

We first analysed the data for this outcome for four groups based on the total dose of TQ used in the trials; 50 to 100 mg, 300 mg, 500 to 600 mg and 1800 to 3000 mg. The analysis indicate that low doses (50 to 100 mg) had outcomes comparable to no treatment (one trial, 162 participants, [Analysis 1.1](#CD010458-fig-00101){ref-type="fig"}) and hence we did not use these groups for further analysis. A repeat analysis of all trials after excluding the low dose groups showed that TQ reduced the *P. vivax* recurrences compared to no treatment during a six month follow‐up (RR 0.13, 95% CI 0.08 to 0.22, three trials, 250 participants, *moderate quality evidence*; [Analysis 1.2](#CD010458-fig-00102){ref-type="fig"}; [Figure 3](#CD010458-fig-0003){ref-type="fig"}).Figure 3Forest plot of comparison: 1 TQ and CQ versus CQ alone, outcome: 1.2 Recurrent *P. vivax* parasitaemia by six months (excluding TQ doses \< 300 mg).

#### Adverse events {#CD010458-sec4-0007}

*Serious adverse events:* We included the low dose TQ groups in the adverse event analysis.There was no difference between TQ groups and controls regarding serious adverse events (three trials, 358 participants, [Analysis 1.3](#CD010458-fig-00103){ref-type="fig"}). No deaths were reported in any of the trials during treatment or follow‐up.

*Any adverse events:* There was no difference for any reported adverse events between the two groups (one trial, 272 participants, [Analysis 1.4](#CD010458-fig-00104){ref-type="fig"}).

We also carried out a dose‐wise comparison (TQ 300 mg and 600 mg) for each type of adverse event reported and found no difference between TQ groups and controls except for a fewer number of chills in the TQ group ([Analysis 1.5](#CD010458-fig-00105){ref-type="fig"}; [Analysis 1.6](#CD010458-fig-00106){ref-type="fig"}).

There was also a dose‐dependent rise in methaemoglobin (MHb) levels in TQ treated groups, which was asymptomatic. In [@CD010458-bbs2-0002] peak levels of MHb were 13.5%, 14.7% and 6.4% in treatment groups with total doses of 2100 mg, 3000 mg and 500 mg, respectively (normal value: 1 to 3%). Similarly, in [@CD010458-bbs2-0003] the highest mean MHb level (12.1%) was reported from the trial arm which had the highest total TQ dose (2100 mg).

All trials screened and excluded patients with G6PD deficiency prior to randomization. Therefore, data on safety of TQ in G6PD‐deficient individuals are currently not available. The longer half‐life of TQ can potentially make it more harmful for patients with G6PD deficiency.

### 2. Tafenoquine versus primaquine {#CD010458-sec3-0022}

Two trials included this comparison ([@CD010458-bbs2-0001]; [@CD010458-bbs2-0003]). Both trials used the same dose of PQ (15 mg/day for 14 days). All patients received CQ 1500 mg for three days. [@CD010458-bbs2-0002] did not have a PQ arm.

#### Recurrent *P. vivax* parasitaemia at six months {#CD010458-sec4-0008}

For purposes of analysis we divided the TQ groups to three subgroups based on the dose (300 mg single dose, 600 mg single dose, and 1800 to 2100 mg in split doses). A single TQ dose of 600 mg may be more effective than PQ in reducing relapses over six months follow‐up (RR 0.29, 95% CI 0.1 to 0.84, two trials, 98 participants, *low quality evidence*; [Analysis 2.1](#CD010458-fig-00201){ref-type="fig"}; [Table 2](#CD010458-tbl-0002){ref-type="table"})*.* The number of events in the higher dose category was too few to draw a firm conclusion. Overall, TQ may be better than PQ (15 mg/day over 14 days) in preventing relapses of vivax malaria during a six month follow‐up (RR 0.3, 95% CI 0.15 to 0.59, two trials, 215 participants, *moderate quality evidence*; [Analysis 2.1](#CD010458-fig-00201){ref-type="fig"}; [Figure 4](#CD010458-fig-0004){ref-type="fig"}).Figure 4Forest plot of comparison: 2 TQ versus PQ (both received CQ), outcome: 2.1 Recurrent *P. vivax* parasitaemia by six months (excluding TQ doses \< 300 mg).

#### Adverse events {#CD010458-sec4-0009}

*Serious adverse events:* the low dose TQ groups were included in the adverse event analysis. There was no difference between TQ and PQ groups with regard to serious adverse events (two trials, 323 participants, *low quality evidence*; [Analysis 2.2](#CD010458-fig-00202){ref-type="fig"}).

*Any adverse events:* There was also no difference detected between the two groups with regard to any reported adverse events (two trials, 323 participants, *low quality evidence*; [Analysis 2.3](#CD010458-fig-00203){ref-type="fig"}). We carried out a dose wise comparison (TQ 300, 600, 1800, 3000 mg) for each type of adverse event reported and still found no difference between TQ and PQ groups (two trials, 323 participants, [Analysis 2.4](#CD010458-fig-00204){ref-type="fig"}; [Analysis 2.5](#CD010458-fig-00205){ref-type="fig"}; [Analysis 2.6](#CD010458-fig-00206){ref-type="fig"}).

Discussion {#CD010458-sec1-0006}
==========

Summary of main results {#CD010458-sec2-0011}
-----------------------

Please see [Table 1](#CD010458-tbl-0001){ref-type="table"} and [Table 2](#CD010458-tbl-0002){ref-type="table"}.

TQ reduced recurrence of vivax malaria (up to six months of observation) when combined with a standard dose of CQ compared to controls who received CQ only (*moderate quality evidence*; further research is likely to have an important impact on our confidence in the estimate of effect). TQ and CQ combination may be superior to PQ and CQ combination at a TQ dose of 600 mg or greater (*low quality evidence*; further research is very likely to have an important impact on this effect and confidence estimates). There was no difference of adverse events (serious or any event) between TQ groups and the controls. The trials that assessed comparable outcomes were consistent in their findings.

Overall completeness and applicability of evidence {#CD010458-sec2-0012}
--------------------------------------------------

[@CD010458-bbs2-0001] is a multicentre, double blind RCT with a larger sample size than other included trials and gives moderate quality evidence to arrive at dosing recommendations of TQ for relapse prevention in patients with vivax parasitaemia. [@CD010458-bbs2-0001] showed that TQ in single low doses (50 and 100 mg) is ineffective in relapse prevention compared to CQ monotherapy and hence should not be used. When the data for higher doses in this trial is pooled with the other two trials (which are open label trials), a benefit is seen for relapse prevention by addition of TQ compared to CQ monotherapy. All trials are consistent in this regard.

The pooled results of the two trials comparing TQ with PQ indicate that TQ may be more effective, but numbers are small.

The dose of PQ used in the control arm in both trials was 15 mg/day for 14 days. More data from further clinical trials are needed to confirm the superiority (if any) of TQ over PQ at this PQ dosage. Current recommendations in some guidelines are for higher doses of PQ (for example, 30 mg/day for 14 days) ([@CD010458-bbs2-0032]) and efficacy of TQ is untested against such doses of PQ. Similarly, G6PD deficient and pregnant individuals were excluded prior to enrolment in all trials and therefore safety of TQ under these circumstances is not explored. Therefore the major disadvantages with PQ, such as haemolysis with G6PD deficiency and methaemoglobinaemia, are still a risk with the structurally similar TQ and same cautions apply for its administration.

Quality of the evidence {#CD010458-sec2-0013}
-----------------------

### Recurrent P. vivax parasitaemia at six months {#CD010458-sec3-0023}

All included trials were randomized prospective well designed clinical trials. However, two were open label trials ([@CD010458-bbs2-0002]; [@CD010458-bbs2-0003]). Still, given the fact that the primary outcome was objectively defined (microscopically defined*P. vivax* parasitaemia), it would have offset any performance or detection bias as long as the microscopists were blinded. Only [@CD010458-bbs2-0002] mentioned that microscopists were blinded. As mentioned previously, the sample size in individual trials was small and specially when the recruits were categorized into four or five treatment arms, the numbers in each arm were even fewer. Several of these arms had high attrition rates at two months. Considering the overall picture, we conclude that further evidence is needed to confirm these findings in larger clinical trials for the TQ versus PQ comparison . Furthermore, the maximum follow‐up was six months in both trials. Relapses of vivax malaria can occur even later, probably up to one year.

### Adverse events {#CD010458-sec3-0024}

Two trials were open label trials ([@CD010458-bbs2-0002]; [@CD010458-bbs2-0003]) which might have caused bias in reporting adverse events. There is no foolproof method of differentiating whether an adverse reaction is actually related to the trial drug. This decision was at the discretion of the investigator and was subjective. The definition of seriousness of an adverse event is also subjective and one trial ([@CD010458-bbs2-0001]) had clearly reported more serious adverse events than the other two trials ([@CD010458-bbs2-0002]; [@CD010458-bbs2-0003]) which had used much higher doses of TQ. Therefore, we have downgraded the quality of evidence to \"low\" with regard to this outcome. The safety of TQ in pregnancy, children and in G6PD deficient patients is untested.

Potential biases in the review process {#CD010458-sec2-0014}
--------------------------------------

The trial registries mentioned above were searched with specific search strategies to uncover any unpublished trials with negative results. None were identified.

Agreements and disagreements with other studies or reviews {#CD010458-sec2-0015}
----------------------------------------------------------

There were no other reviews to compare with this Cochrane review on the efficacy of TQ in preventing relapses of vivax malaria. On adverse events we agree with the conclusion of individual trial investigators and other reviewers ([@CD010458-bbs2-0034]) that TQ is a well‐tolerated drug in non‐pregnant, non‐G6PD deficient individuals in the dose ranges tested.

Authors\' conclusions {#CD010458-sec1-0007}
=====================

TQ has good efficacy in preventing relapses up to six months by clearing vivax hypnozoites when used at a total dose of 300 mg or more (*moderate quality evidence*). Evidence from two studies also suggest that it may be better than PQ (15 mg/day for 14 days) for hypnozoite clearance (*low quality evidence*). The ability to administer TQ as single doses or a shorter course of split doses is a significant advantage.People with G6PD deficiency were excluded from the studies so recommendations for its use derived from trials to date can only be in people in whom G6PD deficiency has been excluded.Further randomized controlled clinical trials will help establish whether TQ is better in relapse prevention compared to PQ. Such trials should test TQ at doses ≥ 300 mg compared to PQ in standard doses(15 mg/day for 14 days). Preferably patients should have a longer follow‐up period (extending to one year).There is a greater potential risk of haemolysis with TQ than with PQ because of the longer half‐life. This is important to consider researching further before deployment of the drug widely in primary care.

CR was supported from a fellowship from the Effective Health Care Research Consortium, which receives funding from UKaid in a grant from UK Government for the benefit of developing countries. We acknowledge Dr. Dulika Sumatipala for her assistance in preparing the protocol. The editorial base for the Cochrane Infectious Diseases Group is supported by UKaid from the UK Government for the benefit of developing countries.

**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^CINAHL, SCOPUS**1malariaMalaria ti, ab, MeSHMalaria ti, ab, MeSHMalaria ti, ab, Emtreemalariamalaria2TafenoquineTafenoquine ti, abTafenoquine ti, abTafenoquine ti, ab, EmtreeTafenoquineTafenoquine31 and 21 and 21 and 21 and 21 and 21 and 24     (randomised controlled trial) or placebo or randomly5     3 and 4

^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([@CD010458-bbs2-0033]).

Comparison 1Tafenoquine versus no hypnozoite treatmentOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Recurrent *P. vivax* parasitaemia by 6 months](#CD010458-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Tafenoquine versus no hypnozoite treatment, Outcome 1 Recurrent *P. vivax* parasitaemia by 6 months.3Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only1.1 Tafenoquine 50 to 100 mg single dose1162Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.55, 1.04\]1.2 Tafenoquine 300 mg single dose1110Risk Ratio (M‐H, Fixed, 95% CI)0.19 \[0.08, 0.41\]1.3 Tafenoquine 500 to 600 mg single dose2122Risk Ratio (M‐H, Fixed, 95% CI)0.14 \[0.06, 0.34\]1.4 Tafenoquine 1800 to 3000 mg split doses263Risk Ratio (M‐H, Fixed, 95% CI)0.05 \[0.01, 0.23\][2 Recurrent *P. vivax* parasitaemia by 6 months (excluding tafenoquine doses \< 300 mg)](#CD010458-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Tafenoquine versus no hypnozoite treatment, Outcome 2 Recurrent *P. vivax* parasitaemia by 6 months (excluding tafenoquine doses \< 300 mg).3250Risk Ratio (M‐H, Fixed, 95% CI)0.13 \[0.08, 0.22\][3 Serious adverse events](#CD010458-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Tafenoquine versus no hypnozoite treatment, Outcome 3 Serious adverse events.3358Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.34, 2.56\][4 Any adverse event by tafenoquine dose](#CD010458-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Tafenoquine versus no hypnozoite treatment, Outcome 4 Any adverse event by tafenoquine dose.1272Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.78, 1.10\][5 Comparison by type of adverse event for tafenoquine 300 mg](#CD010458-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Tafenoquine versus no hypnozoite treatment, Outcome 5 Comparison by type of adverse event for tafenoquine 300 mg.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only5.1 Abdominal pain1110Risk Ratio (M‐H, Fixed, 95% CI)1.16 \[0.38, 3.57\]5.2 Nausea1110Risk Ratio (M‐H, Fixed, 95% CI)1.61 \[0.40, 6.40\]5.3 Vomiting1110Risk Ratio (M‐H, Fixed, 95% CI)4.82 \[0.24, 98.24\]5.4 Diarrhoea1110Risk Ratio (M‐H, Fixed, 95% CI)0.72 \[0.17, 3.08\]5.5 Chills1110Risk Ratio (M‐H, Fixed, 95% CI)0.24 \[0.10, 0.60\]5.6 Vertigo/dizziness1110Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.30, 3.14\]5.7 Headache1110Risk Ratio (M‐H, Fixed, 95% CI)0.48 \[0.25, 0.93\]5.8 Myalgia1110Risk Ratio (M‐H, Fixed, 95% CI)0.32 \[0.03, 3.00\]5.9 Rash/pruritus1110Risk Ratio (M‐H, Fixed, 95% CI)1.10 \[0.43, 2.83\]5.10 Weakness/asthenia1110Risk Ratio (M‐H, Fixed, 95% CI)2.89 \[0.12, 69.55\]5.11 Cough1110Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.25, 3.66\]5.12 Arthralgia1110Risk Ratio (M‐H, Fixed, 95% CI)1.93 \[0.18, 20.65\]5.13 Insomnia1110Risk Ratio (M‐H, Fixed, 95% CI)4.82 \[0.58, 39.94\]5.14 Anaemia/drop in Hb1110Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.06, 15.03\]5.15 QT prolongation1110Risk Ratio (M‐H, Fixed, 95% CI)0.72 \[0.17, 3.08\][6 Comparison by type of adverse event for tafenoquine 600 mg](#CD010458-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Tafenoquine versus no hypnozoite treatment, Outcome 6 Comparison by type of adverse event for tafenoquine 600 mg.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only6.1 Abdominal pain1108Risk Ratio (M‐H, Fixed, 95% CI)1.2 \[0.39, 3.70\]6.2 Nausea1108Risk Ratio (M‐H, Fixed, 95% CI)1.67 \[0.42, 6.63\]6.3 Vomiting1108Risk Ratio (M‐H, Fixed, 95% CI)7.0 \[0.37, 132.35\]6.4 Diarrhoea1108Risk Ratio (M‐H, Fixed, 95% CI)2.25 \[0.74, 6.87\]6.5 Chills1108Risk Ratio (M‐H, Fixed, 95% CI)0.45 \[0.23, 0.90\]6.6 Vertigo/dizziness1108Risk Ratio (M‐H, Fixed, 95% CI)0.8 \[0.23, 2.82\]6.7 Headache1108Risk Ratio (M‐H, Fixed, 95% CI)0.8 \[0.47, 1.37\]6.8 Myalgia1108Risk Ratio (M‐H, Fixed, 95% CI)1.0 \[0.21, 4.74\]6.9 Rash/pruritus1108Risk Ratio (M‐H, Fixed, 95% CI)0.29 \[0.06, 1.31\]6.10 Weakness/asthenia1108Risk Ratio (M‐H, Fixed, 95% CI)11.0 \[0.62, 194.17\]6.11 Cough1108Risk Ratio (M‐H, Fixed, 95% CI)0.25 \[0.03, 2.16\]6.12 Arthralgia1108Risk Ratio (M‐H, Fixed, 95% CI)3.0 \[0.32, 27.94\]6.13 Insomnia1108Risk Ratio (M‐H, Fixed, 95% CI)3.0 \[0.32, 27.94\]6.14 Anaemia/drop in Hb1108Risk Ratio (M‐H, Fixed, 95% CI)1.0 \[0.06, 15.58\]6.15 QT prolongation1108Risk Ratio (M‐H, Fixed, 95% CI)0.25 \[0.03, 2.16\]

Comparison 2Tafenoquine versus primaquineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Recurrent *P. vivax* parasitaemia by 6 months (excluding tafenoquine doses \< 300 mg)](#CD010458-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Tafenoquine versus primaquine, Outcome 1 Recurrent *P. vivax* parasitaemia by 6 months (excluding tafenoquine doses \< 300 mg).2215Risk Ratio (M‐H, Fixed, 95% CI)0.30 \[0.15, 0.59\]1.1 Tafenoquine 300 mg single dose179Risk Ratio (M‐H, Fixed, 95% CI)0.41 \[0.15, 1.14\]1.2 Tafenoquine 600 mg single dose298Risk Ratio (M‐H, Fixed, 95% CI)0.29 \[0.10, 0.84\]1.3 Tafenoquine 1800 to 2100 mg split doses138Risk Ratio (M‐H, Fixed, 95% CI)0.06 \[0.00, 1.10\][2 Serious adverse events](#CD010458-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Tafenoquine versus primaquine, Outcome 2 Serious adverse events.2323Risk Ratio (M‐H, Fixed, 95% CI)0.47 \[0.20, 1.08\][3 Any adverse event by tafenoquine dose](#CD010458-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Tafenoquine versus primaquine, Outcome 3 Any adverse event by tafenoquine dose.2323Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[0.87, 1.28\][4 Comparison by type of adverse event for tafenoquine 300 mg](#CD010458-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Tafenoquine versus primaquine, Outcome 4 Comparison by type of adverse event for tafenoquine 300 mg.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only4.1 Abdominal pain1103Risk Ratio (M‐H, Fixed, 95% CI)0.72 \[0.26, 1.99\]4.2 Nausea1103Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.30, 3.68\]4.3 Vomiting1103Risk Ratio (M‐H, Fixed, 95% CI)0.34 \[0.07, 1.65\]4.4 Diarrhoea1103Risk Ratio (M‐H, Fixed, 95% CI)0.63 \[0.15, 2.67\]4.5 Chills1103Risk Ratio (M‐H, Fixed, 95% CI)0.42 \[0.15, 1.14\]4.6 Vertigo/dizziness1103Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.26, 2.72\]4.7 Headache1103Risk Ratio (M‐H, Fixed, 95% CI)0.60 \[0.29, 1.22\]4.8 Myalgia1103Risk Ratio (M‐H, Fixed, 95% CI)0.42 \[0.04, 4.48\]4.9 Rash/pruritus1103Risk Ratio (M‐H, Fixed, 95% CI)2.24 \[0.63, 7.96\]4.10 Weakness/asthenia1103Risk Ratio (M‐H, Fixed, 95% CI)2.53 \[0.11, 60.60\]4.11 Cough1103Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.22, 3.18\]4.12 Arthralgia1103Risk Ratio (M‐H, Fixed, 95% CI)1.68 \[0.16, 17.94\]4.13 Insomnia1103Risk Ratio (M‐H, Fixed, 95% CI)1.40 \[0.35, 5.55\]4.14 Anaemia/drop in Hb1103Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.05, 13.06\]4.15 QT prolongation1103Risk Ratio (M‐H, Fixed, 95% CI)0.50 \[0.13, 2.00\][5 Comparison by type of adverse event for tafenoquine 600 mg](#CD010458-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Tafenoquine versus primaquine, Outcome 5 Comparison by type of adverse event for tafenoquine 600 mg.2Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only5.1 Abdominal pain2129Risk Ratio (M‐H, Fixed, 95% CI)0.75 \[0.27, 2.06\]5.2 Nausea2129Risk Ratio (M‐H, Fixed, 95% CI)1.23 \[0.39, 3.90\]5.3 Vomiting2129Risk Ratio (M‐H, Fixed, 95% CI)0.69 \[0.21, 2.32\]5.4 Diarrhoea2129Risk Ratio (M‐H, Fixed, 95% CI)1.70 \[0.62, 4.68\]5.5 Chills2129Risk Ratio (M‐H, Fixed, 95% CI)0.78 \[0.35, 1.76\]5.6 Vertigo/dizziness2129Risk Ratio (M‐H, Fixed, 95% CI)0.81 \[0.33, 2.01\]5.7 Headache2129Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.49, 1.48\]5.8 Myalgia2129Risk Ratio (M‐H, Fixed, 95% CI)1.31 \[0.23, 7.48\]5.9 Rash/pruritus2129Risk Ratio (M‐H, Fixed, 95% CI)0.74 \[0.18, 3.11\]5.10 Weakness/asthenia2129Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.41, 1.92\]5.11 Cough1101Risk Ratio (M‐H, Fixed, 95% CI)0.22 \[0.03, 1.88\]5.12 Arthralgia1101Risk Ratio (M‐H, Fixed, 95% CI)2.61 \[0.28, 24.26\]5.13 Insomnia1101Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.18, 4.11\]5.14 Anaemia/drop in Hb1101Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.06, 13.53\]5.15 QT prolongation1101Risk Ratio (M‐H, Fixed, 95% CI)0.17 \[0.02, 1.44\][6 Comparison by type of adverse event for tafenoquine doses \> 600 mg](#CD010458-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Tafenoquine versus primaquine, Outcome 6 Comparison by type of adverse event for tafenoquine doses \> 600 mg.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only6.1 Abdominal pain142Risk Ratio (M‐H, Fixed, 95% CI)3.77 \[0.22, 65.19\]6.2 Nausea142Risk Ratio (M‐H, Fixed, 95% CI)3.77 \[0.22, 65.19\]6.3 Vomiting142Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]6.4 Diarrhoea142Risk Ratio (M‐H, Fixed, 95% CI)1.6 \[0.20, 12.89\]6.5 Chills142Risk Ratio (M‐H, Fixed, 95% CI)1.26 \[0.05, 28.90\]6.6 Vertigo/dizziness142Risk Ratio (M‐H, Fixed, 95% CI)2.13 \[0.76, 6.01\]6.7 Headache142Risk Ratio (M‐H, Fixed, 95% CI)0.8 \[0.30, 2.17\]6.8 Myalgia146Risk Ratio (M‐H, Fixed, 95% CI)1.65 \[0.07, 38.22\]6.9 Rash/pruritus146Risk Ratio (M‐H, Fixed, 95% CI)1.60 \[0.18, 14.16\]6.10 Weakness/asthenia142Risk Ratio (M‐H, Fixed, 95% CI)0.9 \[0.55, 1.48\]

We changed the title from \"Tafenoquine for *Plasmodium vivax* malaria infection\" in the protocol to \"Tafenoquine for preventing relapse in people with *Plasmodium vivax* malaria\" with the concurrence of the CIDG.

The protocol mentions that the efficacy of TQ is to be assessed on three domains: a) radical cure, b) primary prophylaxis and c) terminal prophylaxis. Since then, we restructured the review with the agreement of the CIDG. During the restructuring process it was decided that assessing three different indications for one drug in a single review is complicated. Therefore this Cochrane review is restricted to trials on relapse prevention of patients with *P. vivax* parasitaemia (radical cure). We have changed the methodology accordingly but search strategies remain the same.

Characteristics of included studies \[ordered by study ID\] {#CD010458-sec2-0019}
===========================================================

[@CD010458-bbs2-0001]MethodsMulticentre double blind RCT\
Trial phase: IIb\
Trial design: parallel group dose ranging trialParticipantsNumber randomized: 329\
Inclusion criteria:\
Males and females aged 16 or older with clinical symptoms of malaria with *P. vivax* mono infection with an asexual parasite density \> 100/µL and \< 100,000/µL of blood\
Exclusion criteria:\
Receiving antimalarial treatment within 30 days of screeningSevere malaria, any clinically significant concurrent illnessSevere vomiting or a haemoglobin concentration \< 7 g/dLPregnancy or G6PD enzyme activity \< 70% of the site medianInterventionsAll participants received the standard adult dose of CQ (1500 mg) over 3 days to eradicate the current infection plus:\
TQ 50 mg single dose (n = 55)TQ 100 mg single dose (n = 57)TQ 300 mg single dose (n = 57)TQ 600 mg single dose (n = 56)No further treatment (n = 54)PQ 15 mg/day for 14 days (n = 50)OutcomesOutcomes included in this review:\
Relapse of microscopically proven *P. vivax* malaria after completing treatment up to 6 monthsAdverse events attributable to TQ\
Outcomes not included in this review:\
Time to relapseParasite clearance timeFever clearance timeNotesLocation: Peru, Brazil, India and Thailand Setting: community health centres and hospitals Endemicity: endemic for vivax malaria Resistance: unknown\
Funding: GlaxoSmithKline, Medicines for Malaria Venture***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"A computer generated randomisation schedule, stratified by baseline parasite count\".Allocation concealment (selection bias)Low risk\"Patients, study staff and GlaxoSmithKline personnel were masked to study treatment allocation\".Blinding of participants and personnel (performance bias) All outcomesLow riskDescribed as \"Double blind, double dummy design\".Blinding of outcome assessment (detection bias) All outcomesLow riskDescribed as \"\"Double blind, double dummy design\".Incomplete outcome data (attrition bias) All outcomesLow riskAttrition rate in all groups was \< 6% of the number randomized.Selective reporting (reporting bias)Low riskAbsolute number of relapses by 6 months is not mentioned. However it can be calculated from available data. The numbers were confirmed by communicating with the authors.Other biasLow riskNone identified.[@CD010458-bbs2-0002]MethodsOpen label RCT\
Trial phase: III\
Trial design: Parallel groupParticipantsNumber randomized: 44\
Inclusion criteria:\
Male and female Thai or ethnic Burmese patients aged 18 to 60 years with *P. vivax* infections (*P. vivax* asexual parasitaemia on thin blood film plus one or more clinical features consistent with malaria)\
Exclusion criteria:\
Marked weight discrepanciesPregnancyG6PD deficiencyInterventionsAll participants received the standard adult dose of CQ (1500 mg) over 3 days to eradicate the current infection plus:\
TQ 300 mg daily for 7 days (n = 15)TQ 500 mg daily for 3 days, followed by 500 mg daily for 3 days beginning 1 week after the first dose (n = 11)TQ 500 mg as a single dose (n = 9)No further treatment (n = 9)OutcomesOutcomes included in this review:\
Relapse of microscopically proven *P. vivax* malaria after completing treatment up to six monthsAdverse events recorded during follow‐up.\
Outcomes not included in this review:\
Time to relapseNotesLocation: Thailand Setting: tertiary care referral centre for infectious diseases Endemicity: no malaria transmission in the location (Bangkok) patients were treated Resistance: not mentioned in paper\
Funding: US Army Medical and Materiel Development Activity (Fort Detrick, Frederick, MD); SmithKline Beecham Pharmaceutical (UK).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Randomised with a computer generated sequence schedule\".Allocation concealment (selection bias)Unclear riskNot described.Blinding of participants and personnel (performance bias) All outcomesLow riskDescribed as \"slide readers were unaware of the patients treatment\".Blinding of outcome assessment (detection bias) All outcomesLow riskDescribed as \"slide readers were unaware of the patients treatment\".Incomplete outcome data (attrition bias) All outcomesHigh riskMore than 50% of participants in group A did not complete follow‐up compared to approximately 10% in other groups.Selective reporting (reporting bias)Low riskThe authors state that they originally planned to only follow‐up for two months but patients were followed up for 6 months.Other biasLow riskNone identified.[@CD010458-bbs2-0003]MethodsOpen label RCT\
Trial phase: III\
Trial design: Parallel groupParticipantsNumber randomized: 80\
Inclusion criteria:\
Male and female Thai or ethnic Burmese patients aged 18 to 55 years with *P. vivax* infections (*P. vivax* asexual parasitaemia on thin blood film plus one or more clinical features consistent with malaria)Weight within 20% of the standards of the populationAbility to take oral medicationNot having received an antimalarial agent for last 14 days\
Exclusion criteria:\
Pregnancy and G6PD deficiencyMixed infectionsHaematocrit \< 25%Protracted vomitingOliguriaSystolic blood pressure \< 90 mmHgLactationConcomitant systemic diseaseInterventionsAll participants received the standard adult dose of CQ (1500 mg) over 3 days to eradicate the current infection plus:\
TQ, 300 mg per day for 7 days (n = 18)TQ, 600 mg per day for 3 days (n = 19)TQ, 600 mg as a single dose (n = 18)No further treatment (n = 13)PQ, 15 mg per day for 14 days (n = 12)OutcomesOutcomes included in this review:\
Relapse of microscopically proven *P. vivax* malaria after completing treatment. Participants were tested daily during drug administration and then two weekly till week 8 and 4 weekly till week 24Adverse events recorded during follow‐up\
Outcomes not included in this review:\
Plasma TQ concentrations of participantsNotesLocation: Thailand\
Setting: tertiary care referral centre for infectious diseases Endemicity: no malaria transmission in the location (Bangkok) patients were treated Resistance: not mentioned in paper\
Funding: US Army Medical and Materiel Development Activity and GlaxoSmithKline (formerly SmithKline Beecham)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThis was a randomized trial with a computer generated block randomization. However, following randomization some patients had been moved between groups and nearly 10 randomizations had been eliminated.Allocation concealment (selection bias)Unclear riskNot described.Blinding of participants and personnel (performance bias) All outcomesUnclear riskDespite being an open label trial, if the microscopists were blinded performance bias would be low. This fact is not mentioned.Blinding of outcome assessment (detection bias) All outcomesUnclear riskDespite being an open label trial, if the microscopists were blinded detection bias would be low. This fact is not mentioned.Incomplete outcome data (attrition bias) All outcomesLow riskAttrition rate was \< 25% in all groups for 2 month follow‐up. There was no attrition in group 5.Selective reporting (reporting bias)Low riskNone identified.Other biasLow riskNone identified.

Characteristics of excluded studies \[ordered by study ID\] {#CD010458-sec2-0020}
===========================================================

StudyReason for exclusion[@CD010458-bbs2-0004]Assesses the efficacy of TQ with regard to prevention of vivax and falciparum malaria during a period of exposure in an endemic area in healthy participants.[@CD010458-bbs2-0005]Describes the same trial by [@CD010458-bbs2-0015][@CD010458-bbs2-0006]Assess the efficacy of TQ for preventing recurrences of vivax malaria in participants without baseline vivax parasitaemia after leaving an endemic area.[@CD010458-bbs2-0007]Assesses QT prolongation with TQ in healthy volunteers.[@CD010458-bbs2-0008]Assesses the efficacy of TQ with regard to prevention of falciparum malaria.[@CD010458-bbs2-0009]Uncontrolled study.[@CD010458-bbs2-0010]Conference proceeding describing the same trial (DETECTIVE) as [@CD010458-bbs2-0001].[@CD010458-bbs2-0011]Assesses the efficacy of TQ with regard to prevention of falciparum malaria.[@CD010458-bbs2-0012]Assess efficacy of TQ for hypnozoite clearance of participants leaving an endemic area (who did not have baseline vivax parasitaemia).[@CD010458-bbs2-0013]Assess the efficacy of TQ for preventing vivax malaria infections in healthy participants during a period of exposure in an endemic area.[@CD010458-bbs2-0014]Assesses the efficacy of TQ with regard to falciparum malaria.[@CD010458-bbs2-0015]Assess the efficacy of TQ for preventing vivax and falciparum malaria during a period of exposure in an endemic area in healthy participants.

Characteristics of ongoing studies \[ordered by study ID\] {#CD010458-sec2-0021}
==========================================================

[@CD010458-bbs2-0016]Trial name or titleA Phase I Study to Investigate the Hemolytic Potential of tafenoquine in Healthy Subjects With Glucose‐6‐phosphate Dehydrogenase Deficiency and the Safety and Tolerability of tafenoquine in Acute *Plasmodium vivax* Malaria Patients With Glucose‐6‐phosphate Dehydrogenase DeficiencyMethodsRandomized open label studyParticipantsInclusion criteria:\
Age 18 to 45 yearsNon‐pregnant non‐lactating womenWHO class III G6PD‐deficiency or G6PD‐normal status must be documented by enzyme activity and cytochemical stainingPositive GIEMSA smear for *P. vivax* with parasite density between 500 to 200,000/µLInterventionsCQ and PQ versus TQOutcomesTo evaluate the safety, tolerability, and haemolytic potential of TQ in G6PD‐deficient female healthy volunteers compared with G6PD‐normal female healthy volunteers. This will be done by measuring maximum absolute decline in haemoglobin from baseline (time frame: 2 years)Starting dateJuly 2009Contact informationUS GSK Clinical Trials Call Center (GSKClinicalSupportHD\@gsk.com), USANotesLocation: Thailand\
Funding: GlaxoSmithKline Pharmaceuticals Ltd.[@CD010458-bbs2-0017]Trial name or titleA Randomized, Active‐control, Double‐blind, Double‐dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of *Plasmodium vivax* in AdultsMethodsRandomized, active‐control, double‐blind, double‐dummy studyParticipantsInclusion criteria:\
Age 20 to 60 yearsPositive GIEMSA smear for *P. vivax* with parasite density between 500 to 200,000/µLWilling to be hospitalized for 29 days and remain in a malaria‐free area for 60 days\
Exclusion criteria:\
Lactating and pregnant femalesInterventionsCQ and PQ for the control arm and TQ for the trial arm for treatmentOutcomesPrimary outcome; adequate clinical responseStarting dateSeptember 2003Contact informationSornchai Looareesuwan, Mahidol University, ThailandNotesLocation: Thailand\
Funding: U.S. Army Medical Research and Materiel Command and GlaxoSmithKline Pharmaceuticals Ltd.[@CD010458-bbs2-0018]Trial name or titleA Randomized, Double‐Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB‐252263, WR238605) Versus Primaquine in the Treatment of Subjects With *Plasmodium Vivax* MalariaMethodsRandomized, double‐blind, double dummy, comparative, multicentre studyParticipantsInclusion criteria:\
Age \> 16 yearsPositive GIEMSA smear for *P. vivax* with parasite density between 100 to 100,000/µLWilling to follow study protocolHb level \> 7 g/dL (for those with a G6PD level \> 70% of site median) or \> 8 g/dL (or those with a G6PD level 40 to 70% of site median)\
Exclusion criteria:\
Lactating, pregnant and sexually active females not using a contraceptive methodAny patient with 4‐ or 8‐aminoquinoline allergy, liver impairment or any other significant illness including QT prolongation on ECG, severe vivax malaria, mixed malaria infection and substance abuseInterventionsCQ and TQ (trial arm) compared with CQ and primaquine and CQ and placebo (control arms)OutcomesPrimary outcome(s):\
Proportion of all subjects with *P. vivax* experiencing clinically relevant haemolysis up to 180 days.Proportion of female subjects with *P. vivax* who are moderately (40 to 70 percent) G6PD deficient experiencing clinically relevant haemolysis.\
Secondary outcomes:\
Adverse events caused by treatment.*P. vivax* relapses within 6 months post treatment.Fever clearance timeGametocyte clearance timeTotal parasite clearance timeCorrelation between plasma TQ levels and haemoglobinMHb levelsTreatment efficacyStarting dateSeptember 2014Contact informationUS GSK Clinical Trials Call CenterNotesLocation: Not mentioned\
Funding: GlaxoSmithKline Pharmaceuticals Ltd and Medicines for Malaria Venture
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^No serious risk of bias: This trial was at low risk of selection and reporting bias. ^2^No serious indirectness: This trial enrolled adults with *P. vivax* malaria in Peru, Thailand, India and Brazil. CQ was given in the standard adult dose to all participants. ^3^Downgraded by 1 for serious imprecision: This single trial is small and had few events during six months, as such this result is at high risk of being a chance finding or of overestimating the true effect. ^4^No serious risk of bias: One trial is at low risk of selection or detection bias. The second smaller trial is at unclear risk of selection bias. ^5^No serious inconsistency. ^6^No serious indirectness: These trials enrolled adults with *P. vivax* malaria in Peru, Thailand, India and Brazil. CQ was given in the standard adult dose to all participants. ^7^Downgraded by 1 for serious imprecision: These two trials are small with few events, as such this result is at high risk of being a chance finding or of overestimating the true effect. ^8^Downgraded by 1 for serious risk of bias: Both trials are at unclear risk of selection bias. ^9^No serious indirectness: These trials enrolled adults with *P. vivax* malaria in Thailand. CQ was given in the standard adult dose to all participants. ^10^Downgraded by 1 for serious indirectness: These trials excluded children, pregnant women and people with G6PD deficiency. ^11^Downgraded by 1 for serious imprecision.

[^3]: ^1^No serious risk of bias: This trial was at low risk of selection and reporting bias. ^2^No serious indirectness: This trial enrolled adults with *P. vivax* malaria in Peru, Thailand, India and Brazil. CQ was given in the standard adult dose to all participants. ^3^Downgraded by 1 for serious imprecision: This single trial is small and had few events during six months, as such this result is at high risk of being a chance finding or of overestimating the true effect. Larger trials are needed to confirm this effect. ^4^Downgraded by 1 for serious imprecision: Both trials are small and had only a few events during six months, as such this result is at high risk of being a chance finding or of overestimating the true effect. Larger trials are needed to confirm this effect. ^5^Downgraded by 1 for serious risk of selection and detection bias in one trial. ^6^Downgraded by 1 for serious indirectness: These trials excluded children, pregnant women and people with G6PD deficiency. ^7^Downgraded by 1 for serious imprecision.

[^4]: CQ: Chloroquine; PQ: Primaquine; TQ: Tafenoquine
